Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gurjyot K Doshi

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|November 16, 2020
Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)Gurjyot K Doshi, Abhijeet Bhanegaonkar, Mairead Kearney, et al.
Frontiers in Oncology|October 18, 2023
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinomaGurjyot K Doshi, Haojie Li, Mehmet Burcu, et al.
JCO Clinical Cancer Informatics|December 20, 2024
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United StatesGurjyot K Doshi, Andrew J Osterland, Ping Shi, et al.
JCO Oncology Practice|May 27, 2025
Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards UpdateLuis E Raez, Xylina T Gregg, Gurjyot K Doshi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Clinicoeconomics and Outcomes Research : CEOR|November 16, 2020
Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)Gurjyot K Doshi, Abhijeet Bhanegaonkar, Mairead Kearney, et al.
Frontiers in Oncology|October 18, 2023
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinomaGurjyot K Doshi, Haojie Li, Mehmet Burcu, et al.
JCO Clinical Cancer Informatics|December 20, 2024
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United StatesGurjyot K Doshi, Andrew J Osterland, Ping Shi, et al.
JCO Oncology Practice|May 27, 2025
Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards UpdateLuis E Raez, Xylina T Gregg, Gurjyot K Doshi, et al.
Pageof 1